A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
M R ValerioN Gebbia

Abstract

We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1-2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1-2 in 19 patients (48%). Twenty-one (53%) patients experienced grade 1-2 peripheral neuropathy. The overall response rate was 46% (95% CI 23.6-68.7). Median progression-free survival was 28 weeks (range 12-52 weeks) and median survival was 45 weeks (range 26-136+ weeks). The mean duration of response was 34 weeks (range 16-52 weeks). In platinum-resistant and -refractory ovarian cancer patients, the overall response rate was 37% (CI 95% 14.4-60.8) with a progression-free survival of 28 weeks (range 12-52 weeks) and a median survival of 42 weeks (range 28-84 we...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Markman, W Hoskins
Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Jan 1, 1981·Cancer·A B MillerA Winkler
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J T ThigpenR J Barrett
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinH E Lambert
Apr 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G J RustinH E Lambert
Dec 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P CholletE Cvitkovic
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M MuggiaL J Liang
Apr 29, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C SessaA du Bois
Nov 26, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S FaivreJ M Extra
Jan 14, 2000·Critical Reviews in Oncology/hematology·N ColomboA Maggioni
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P NeijtH C van Houwelingen
Dec 21, 2000·JAMA : the Journal of the American Medical Association·B Vastag
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F Ozols
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V DierasP Pouillart
Sep 10, 2002·The Lancet Oncology·Mark Harries, Martin Gore
Jun 6, 2003·The Lancet Oncology·Stephen Chan
Jul 19, 2003·Seminars in Oncology·Ami P Vaidya, John P Curtin
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A González-Martín, UNKNOWN Geico Group
Dec 10, 2003·Seminars in Oncology·Ann H PartridgeHarold J Burstein

❮ Previous
Next ❯

Citations

Jan 22, 2009·Cancer Chemotherapy and Pharmacology·Jalid SehouliUNKNOWN North-Eastern German Society of Gynecological Oncology
Mar 17, 2005·Breast Cancer Research and Treatment·Julie R Gralow
Mar 17, 2005·Breast Cancer Research and Treatment·William J Gradishar
Apr 5, 2011·Antioxidants & Redox Signaling·Laura A A Gilliam, Daret K St Clair
May 22, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y YildirimS Tinar
Mar 26, 2011·Expert Opinion on Drug Metabolism & Toxicology·Matteo MorottiSimone Ferrero
Mar 27, 2007·Cancer Treatment Reviews·Britta StordalRoss Davey
Dec 17, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gregor SeligerHans-Joachim Schmoll

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.